Skip to main content

Table 2 In vitro susceptibilities of Gram-positive strains obtained from the ATLAS program, 2012–2016.

From: Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

Organism/antibiotic

No. of isolates

MIC50

MIC90

MIC range

CLSI

EUCAST

S%

I%

R%

S%

I%

R%

Staphylococcus aureus

Ceftaroline

50525

0.5

1

0.015–64

93.4

6.2

0.4

93.4

6.2

0.4

Ceftazidime–avibactam

50525

32

64

0.015–64

NA

NA

NA

NA

NA

NA

Ceftazidime

50525

32

64

0.015–64

NA

NA

NA

NA

NA

NA

Pip-taz

50525

8

32

0.12–32

NA

NA

NA

NA

NA

NA

Levofloxacin

50525

0.5

8

0.015–8

56.9

0.4

42.7

56.9

0

43.1

Moxifloxacin

50525

0.12

4

0.008–8

57.1

2.7

40.1

56.8

0

43.2

Tigecycline

50525

0.12

0.25

0.015–4

98.9

1.1

0

98.9

0

1.1

Minocycline

50525

0.12

1

0.12–16

93.2

3.4

3.4

89.4

1.4

9.2

Gentamicin

31019

0.5

64

0.06–64

85

0.7

14.3

56.1

0

43.9

Daptomycin

50525

0.5

1

0.06–4

99.8

0.2

0

99.8

0

0.2

Trimethoprim sulfa

31019

0.25

1

0.25–8

96.8

0

3.3

96.8

0.7

2.6

Teicoplanin

50525

0.5

1

0.12–32

100

0

0

98.1

0

1.9

Vancomycin

50525

1

2

0.25–4

100

0

0

100

0

0

Clindamycin

50525

0.12

4

0.03–8

74.8

0.3

24.9

74.2

0.6

25.2

Erythromycin

50525

1

16

0.12–16

48

3.4

48.6

50.6

0.3

49.1

Linezolid

50525

2

2

0.5–16

100

0

0

100

0

0

Oxacillin

50525

4

8

0.06–8

40.4

0

59.6

NA

NA

NA

Streptococcus pneumoniae

Ceftaroline

11005

0.008

0.12

0.004–32

99.7

0.3

0

98.7

0

1.3

Ceftazidime–avibactam

11005

0.25

16

0.015–128

NA

NA

NA

NA

NA

NA

Ceftazidime

11005

0.25

16

0.015–128

NA

NA

NA

NA

NA

NA

Doripenem

11005

0.015

1

0.015–8

98

2

0

98

0

2

Meropenem

11005

0.015

1

0.008–2

78

9.2

12.8

100

0

0

Levofloxacin

11005

1

1

0.12–16

98.5

0.2

1.3

98.5

0

1.5

Moxifloxacin

11005

0.12

0.25

0.03–8

98.5

0.5

1.1

98.4

0

1.6

Tigecycline

11005

0.03

0.03

0.008–2

99.9

0.1

0

NA

NA

NA

Minocycline

11005

0.12

4

0.015–4

71.3

5.1

23.6

69.6

1.7

28.7

Daptomycin

11005

0.25

0.5

0.03–8

NA

NA

NA

NA

NA

NA

Vancomycin

11005

0.25

0.5

0.008–2

100

0

0

100

0

0

Clindamycin

11005

0.06

2

0.008–2

74.8

0.4

24.8

75.2

0

24.8

Erythromycin

11005

0.06

2

0.008–2

64.3

0.3

35.4

64.3

0.3

35.4

Linezolid

11005

1

2

0.06–4

100

0

0

100

0

0

Penicillin

11005

0.03

2

0.015–16

61.8

20.7

17.5

61.8

28.9

9.3

α-hemolytic Streptococcus

Ceftaroline

12138

0.008

0.12

0.004–32

99.7

0.3

0

98.7

0

1.3

Ceftazidime–avibactam

12138

0.25

16

0.015–128

NA

NA

NA

NA

NA

NA

Ceftazidime

12138

0.25

16

0.015–128

NA

NA

NA

NA

NA

NA

Penicillin

12138

0.03

2

0.015–16

NA

NA

NA

NA

NA

NA

Doripenem

12138

0.015

1

0.015–8

NA

NA

NA

98

0

2

Meropenem

12138

0.015

1

0.008–2

NA

NA

NA

100

0

0

Levofloxacin

12138

1

2

0.12–16

98.3

0.3

1.4

98.5

0

1.5

Moxifloxacin

12138

0.12

0.25

0.03–8

98.5

0.5

1.1

98.4

0

1.6

Minocycline

12138

0.12

4

0.015–4

NA

NA

NA

69.6

1.7

28.7

Tigecycline

12138

0.03

0.03

0.008–2

NA

NA

NA

100

0

0

Clindamycin

12138

0.06

2

0.008–2

75.6

0.4

24.1

75.9

0

24.1

Erythromycin

12138

0.06

2

0.008–2

64.8

0.3

34.9

64.3

0.3

35.4

Vancomycin

12138

0.5

0.5

0.008–2

100

0

0

100

0

0

Linezolid

12138

1

2

0.06–8

100

0

0

100

0

0

Daptomycin

12138

0.25

0.5

0.03–8

99.3

0.7

0

100

0

0

β-hemolytic Streptococcus

Ceftaroline

9019

0.004

0.015

0.004–1

100

0

0

NA

NA

NA

Ceftazidime–avibactam

9019

0.12

0.5

0.015–128

NA

NA

NA

NA

NA

NA

Ceftazidime

9019

0.12

0.5

0.015–128

NA

NA

NA

NA

NA

NA

Penicillin

9019

0.015

0.06

0.015–8

NA

NA

NA

NA

NA

NA

Doripenem

9019

0.015

0.03

0.015–8

NA

NA

NA

100

0

0

Meropenem

9019

0.015

0.06

0.008–2

99.9

0.1

0

100

0

0

Levofloxacin

9019

0.5

1

0.12–16

98.3

0.2

1.5

98.2

0

1.9

Moxifloxacin

9019

0.12

0.25

0.03–8

NA

NA

NA

98.1

0

1.9

Minocycline

9019

0.12

4

0.015–4

69.9

30.1

0

65.6

0.9

33.4

Tigecycline

9019

0.03

0.06

0.008–2

100

0

0

100

0

0

Clindamycin

9019

0.06

0.12

0.008–2

90.6

0.3

9

91

0

9

Erythromycin

9019

0.06

2

0.008–2

83.4

0.7

15.8

84.4

0.6

15

Vancomycin

9019

0.5

0.5

0.008–1

100

0

0

100

0

0

Linezolid

9019

1

2

0.06–8

100

0

0

100

0

0

Daptomycin

9019

0.12

0.5

0.03–8

100

0

0

100

0

0

CoNS

Ceftaroline

8490

0.25

1

0.015–64

NA

NA

NA

NA

NA

NA

Ceftazidime–avibactam

8490

16

64

0.015–64

NA

NA

NA

NA

NA

NA

Ceftazidime

8490

16

64

0.015–64

NA

NA

NA

NA

NA

NA

Pip-taz

8490

2

32

0.12–32

NA

NA

NA

NA

NA

NA

Levofloxacin

8490

4

8

0.015–8

46.9

1.8

51.4

46.9

0

53.1

Moxifloxacin

8490

1

4

0.008–8

NA

NA

NA

NA

NA

NA

Minocycline

8490

0.25

0.5

0.12–16

48.9

14.6

36.5

46.5

0

53.5

Tigecycline

8490

0.25

0.5

0.015–4

98.7

1.3

0

98.7

0

1.3

Clindamycin

8490

0.12

8

0.03–8

65.5

2.1

32.4

63.7

1.9

34.5

Erythromycin

8490

8

16

0.12–16

33.1

1.1

65.8

33.4

0.3

66.3

Vancomycin

8490

1

2

0.25–8

99.9

0.1

0

99.9

0

0.1

Teicoplanin

8490

2

8

0.12–64

98

1.7

0.3

85

0

15

Linezolid

8490

1

2

0.5–16

99.4

0

0.6

99.4

0

0.6

Daptomycin

8490

0.5

1

0.06–4

99.6

0.4

0

99.6

0

0.4

Gentamicin

5336

2

64

0.06–64

54.7

5.5

39.8

33.8

0

66.3

Trimethoprim sulfa

5336

1

8

0.25–8

61

0

39

61

10

28.9

Oxacillin

8490

4

8

0.06–8

25.7

0

74.3

NA

NA

NA

Enterococcus faecalis

Ceftaroline

3194

1

16

0.015–64

NA

NA

NA

NA

NA

NA

Ceftazidime–avibactam

3194

64

64

1–64

NA

NA

NA

NA

NA

NA

Ceftazidime

3194

64

64

1–64

NA

NA

NA

NA

NA

NA

Levofloxacin

3194

1

16

0.06–16

68

1.1

30.8

NA

NA

NA

Tigecycline

3194

0.12

0.25

0.015–4

94.1

5.9

0

94.1

3.9

2

Minocycline

3194

16

16

0.06–16

25.8

13.7

60.5

NA

NA

NA

Daptomycin

3194

2

4

0.06–8

99.8

0.2

0

NA

NA

NA

Teicoplanin

3194

0.5

0.5

0.12–64

98.3

0.1

1.7

97.8

0

2.2

Vancomycin

3194

1

2

0.12–64

94.3

3.8

1.9

94.3

0

5.7

Erythromycin

3194

16

16

0.06–16

14.6

27.4

58

NA

NA

NA

Linezolid

3194

1

2

0.06–8

99.3

0.6

0.2

99.8

0

0.2

Quinupristin dalfopristin

2014

8

16

0.25–16

1

7.7

91.3

NA

NA

NA

Enterococcus faecium

Ceftaroline

2546

64

64

0.03–64

NA

NA

NA

NA

NA

NA

Ceftazidime–avibactam

2546

64

64

0.12–64

NA

NA

NA

NA

NA

NA

Ceftazidime

2546

64

64

0.12–64

NA

NA

NA

NA

NA

NA

Levofloxacin

2546

16

16

0.06–16

12.2

3.9

83.9

NA

NA

NA

Tigecycline

2546

0.12

0.25

0.015–8

95.5

4.5

0

95.5

3

1.5

Minocycline

2546

2

16

0.06–16

55.4

12.4

32.2

NA

NA

NA

Daptomycin

2546

4

4

0.06–16

98

2

0

NA

NA

NA

Teicoplanin

2546

1

64

0.12–64

76

1

23

75.2

0

24.8

Vancomycin

2546

1

64

0.12–64

69.2

5

25.8

69.2

0

30.8

Erythromycin

2546

16

16

0.06–16

3.6

11.2

85.2

NA

NA

NA

Linezolid

2546

1

2

0.06–16

97.4

2.5

0.2

99.8

0

0.2

Quinupristin dalfopristin

1577

1

4

0.06–16

73.2

13.9

12.9

NA

NA

NA

  1. CLSI Clinical Laboratory and Standards Institute, EUCAST European Committee on Antimicrobial Susceptibility Testing, NA not applicable, CoNS coagulase-negative staphylococci